ATE426594T1 - Verfahren zur herstellung von inhibitoren der hmg-coa-reduktase - Google Patents
Verfahren zur herstellung von inhibitoren der hmg-coa-reduktaseInfo
- Publication number
- ATE426594T1 ATE426594T1 AT03734716T AT03734716T ATE426594T1 AT E426594 T1 ATE426594 T1 AT E426594T1 AT 03734716 T AT03734716 T AT 03734716T AT 03734716 T AT03734716 T AT 03734716T AT E426594 T1 ATE426594 T1 AT E426594T1
- Authority
- AT
- Austria
- Prior art keywords
- coa reductase
- reductase inhibitors
- sub
- img
- hmg
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D215/14—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Quinoline Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35378702P | 2002-01-31 | 2002-01-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE426594T1 true ATE426594T1 (de) | 2009-04-15 |
Family
ID=27663254
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03734716T ATE426594T1 (de) | 2002-01-31 | 2003-01-30 | Verfahren zur herstellung von inhibitoren der hmg-coa-reduktase |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US7371865B2 (de) |
| EP (1) | EP1472228B1 (de) |
| JP (1) | JP4524111B2 (de) |
| KR (1) | KR20040081161A (de) |
| CN (1) | CN1305853C (de) |
| AT (1) | ATE426594T1 (de) |
| AU (1) | AU2003226971B2 (de) |
| BR (1) | BR0307303A (de) |
| CA (1) | CA2472776C (de) |
| CO (1) | CO5601005A2 (de) |
| DE (1) | DE60326819D1 (de) |
| EC (1) | ECSP045214A (de) |
| ES (1) | ES2323267T3 (de) |
| HK (1) | HK1070651A1 (de) |
| IL (1) | IL162980A (de) |
| MX (1) | MXPA04007396A (de) |
| NO (1) | NO327091B1 (de) |
| NZ (1) | NZ534232A (de) |
| PL (1) | PL370658A1 (de) |
| PT (1) | PT1472228E (de) |
| RU (1) | RU2299196C2 (de) |
| WO (1) | WO2003064392A1 (de) |
| ZA (1) | ZA200405322B (de) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100374422C (zh) * | 2003-02-12 | 2008-03-12 | 西巴特殊化学品控股有限公司 | 匹伐他汀钙的晶形 |
| WO2004094385A1 (ja) * | 2003-04-24 | 2004-11-04 | Daicel Chemical Industries, Ltd. | （３ｒ，５ｓ，６ｅ）－７－［２－シクロプロピル－４－（４－フルオロフェニル）キノリン－３－イル］－３，５－ジヒドロキシ－６－ヘプテン酸エチルの製造方法 |
| TWI328006B (en) * | 2003-12-26 | 2010-08-01 | Nissan Chemical Ind Ltd | Crystal form of quinoline compound and process for its production |
| WO2006035286A2 (en) * | 2004-09-27 | 2006-04-06 | Ranbaxy Laboratories Limited | Process for preparating enantiomerically pure fluvastatin sodium and a novel polymorphic form thereof |
| HUE027872T2 (en) * | 2006-05-03 | 2016-11-28 | Msn Laboratories Private Ltd | A novel process for statins and their pharmaceutically acceptable salts |
| ES2567171T3 (es) * | 2006-10-09 | 2016-04-20 | Msn Laboratories Private Limited | Nuevo procedimiento para la preparación de estatinas y sus sales farmacéuticamente aceptables |
| EP2172471B1 (de) * | 2007-04-18 | 2013-03-27 | Teva Pharmaceutical Industries, Ltd. | Verfahren zur Herstellung von Zwiechenverbindungen von HMG-CoA reductase Inhibitoren |
| WO2009009152A1 (en) * | 2007-07-12 | 2009-01-15 | Teva Pharmaceutical Industries Ltd. | Rosuvastatin intermediates and their preparation |
| US8487105B2 (en) * | 2009-01-19 | 2013-07-16 | Msn Laboratories Limited | Process for preparing pitavastatin, intermediates and pharmaceuctically acceptable salts thereof |
| KR101160152B1 (ko) * | 2009-02-24 | 2012-06-27 | 한미사이언스 주식회사 | 스타틴 화합물 또는 그 염의 신규 제조방법, 및 이에 사용되는 중간체 화합물 |
| EP2526099B1 (de) | 2010-01-18 | 2016-03-30 | MSN Laboratories Limited | Verbessertes verfahren zur herstellung von amid-zwischenprodukten und seine anwendung |
| WO2011104725A2 (en) * | 2010-02-23 | 2011-09-01 | Cadila Healthcare Limited | Hmg-coa reductase inhibitors and process for the preparation thereof |
| EP2383260A3 (de) | 2010-04-30 | 2011-12-28 | Dipharma Francis S.r.l. | Verfahren zur Herstellung von Statine |
| WO2011141934A1 (en) | 2010-05-13 | 2011-11-17 | Matrix Laboratories Ltd. | An improved process for the preparation of an intermediate of hmg-coa reductase inhibitors |
| CN105153010B (zh) * | 2010-07-01 | 2018-06-08 | 柳韩洋行 | HMG-CoA还原酶抑制剂及其中间体的制备方法 |
| EP3178812A1 (de) * | 2010-11-12 | 2017-06-14 | Hetero Research Foundation | Neuartige polymorphe von pitavastatin-calcium |
| JP6181063B2 (ja) | 2011-11-28 | 2017-08-16 | マイラン ラボラトリーズ リミテッドＭｙｌａｎ Ｌａｂｏｒａｔｏｒｉｅｓ Ｌｉｍｉｔｅｄ | ＨＭＧ−ＣｏＡレダクターゼ阻害剤の中間体の新規な製造方法 |
| CN103288871A (zh) * | 2012-02-28 | 2013-09-11 | 浙江京新药业股份有限公司 | 一种制备二羟基酸HMG-CoA还原酶抑制剂用的中间体及其制备方法和应用 |
| ITVI20130039A1 (it) | 2013-02-20 | 2014-08-21 | F I S Fabbrica Italiana Sint I S P A | Processo per la preparazione di intermedi chiave per la sintesi di statine |
| CN103172656B (zh) * | 2013-04-02 | 2015-07-08 | 浙江科技学院 | 3-二甲基叔丁基硅氧基戊二酸酐的合成工艺 |
| CN111518035A (zh) * | 2020-06-18 | 2020-08-11 | 安徽鼎旺医药有限公司 | 一种瑞舒伐他汀叔丁胺盐及其制备方法 |
| CN113683539B (zh) * | 2021-09-23 | 2023-05-16 | 上海裕兰生物科技有限公司 | 一种聚酮中间体的合成方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5354772A (en) * | 1982-11-22 | 1994-10-11 | Sandoz Pharm. Corp. | Indole analogs of mevalonolactone and derivatives thereof |
| US4650890A (en) * | 1984-04-03 | 1987-03-17 | Sandoz Corp. | Preparation of olefinic compounds and intermediates thereof |
| JP2569746B2 (ja) * | 1987-08-20 | 1997-01-08 | 日産化学工業株式会社 | キノリン系メバロノラクトン類 |
| CA1336714C (en) | 1987-08-20 | 1995-08-15 | Yoshihiro Fujikawa | Quinoline type mevalonolactone inhibitors of cholesterol biosynthesis |
| US4804770A (en) * | 1988-04-29 | 1989-02-14 | E. R. Squibb & Sons, Inc. | Process for preparing a keto-phosphonate intermediate useful in preparing HMG-CoA reductase inhibitors |
| DE3911064A1 (de) * | 1989-04-06 | 1990-10-11 | Bayer Ag | Substituierte 1,8-naphthyridine |
| US5049577A (en) * | 1990-01-29 | 1991-09-17 | E. R. Squibb & Sons, Inc. | 2-pyrrolidone substituted dihydroxy alkanoic, alkenoic and alkynoic acids, compositions and HMG-CoA reductase inhibition therewith |
| JP3528186B2 (ja) | 1991-06-24 | 2004-05-17 | 日産化学工業株式会社 | 光学活性キノリンメバロン酸のジアステレオマー塩 |
| DK1341785T3 (da) * | 2000-11-16 | 2009-01-26 | Teva Pharma | Hydrolyse af R (R*,R*)-2-(4-fluorphenyl)-beta.delta-dihydroxy-5 (1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrol-1-heptansyrester med calciumhydroxid |
| EP1365029A4 (de) * | 2001-02-02 | 2009-07-29 | Mitsubishi Chem Corp | "verfahren zur darstellung von (3r,5s)-(e)-7- 2-cyclopropyl-4-(4-fluorphenyl)-chinolin-3-yl -3,5-dihydroxyhept-6-ensäureestern" |
| PT1466905E (pt) * | 2001-11-14 | 2011-07-14 | Nissan Chemical Ind Ltd | Processo para a produção de éster do ácido oxo-heptenóico opticamente activo |
| US6835838B2 (en) * | 2002-01-28 | 2004-12-28 | Novartis Ag | Process for the manufacture of organic compounds |
| GB0210234D0 (en) * | 2002-05-03 | 2002-06-12 | Novartis Ag | Process for the manufacture of organic compounds |
-
2003
- 2003-01-30 CA CA2472776A patent/CA2472776C/en not_active Expired - Fee Related
- 2003-01-30 PT PT03734716T patent/PT1472228E/pt unknown
- 2003-01-30 JP JP2003564015A patent/JP4524111B2/ja not_active Expired - Lifetime
- 2003-01-30 EP EP03734716A patent/EP1472228B1/de not_active Expired - Lifetime
- 2003-01-30 US US10/502,177 patent/US7371865B2/en not_active Expired - Lifetime
- 2003-01-30 PL PL03370658A patent/PL370658A1/xx not_active Application Discontinuation
- 2003-01-30 DE DE60326819T patent/DE60326819D1/de not_active Expired - Lifetime
- 2003-01-30 AT AT03734716T patent/ATE426594T1/de active
- 2003-01-30 RU RU2004126442/04A patent/RU2299196C2/ru not_active IP Right Cessation
- 2003-01-30 NZ NZ534232A patent/NZ534232A/xx not_active IP Right Cessation
- 2003-01-30 AU AU2003226971A patent/AU2003226971B2/en not_active Ceased
- 2003-01-30 BR BR0307303-3A patent/BR0307303A/pt not_active IP Right Cessation
- 2003-01-30 KR KR10-2004-7011808A patent/KR20040081161A/ko active IP Right Grant
- 2003-01-30 MX MXPA04007396A patent/MXPA04007396A/es active IP Right Grant
- 2003-01-30 ES ES03734716T patent/ES2323267T3/es not_active Expired - Lifetime
- 2003-01-30 CN CNB038027402A patent/CN1305853C/zh not_active Expired - Lifetime
- 2003-01-30 WO PCT/EP2003/000954 patent/WO2003064392A1/en active Application Filing
-
2004
- 2004-07-05 ZA ZA2004/05322A patent/ZA200405322B/en unknown
- 2004-07-12 IL IL162980A patent/IL162980A/en not_active IP Right Cessation
- 2004-07-30 EC EC2004005214A patent/ECSP045214A/es unknown
- 2004-08-10 CO CO04077715A patent/CO5601005A2/es not_active Application Discontinuation
- 2004-08-30 NO NO20043611A patent/NO327091B1/no not_active IP Right Cessation
-
2005
- 2005-04-18 HK HK05103286.2A patent/HK1070651A1/xx not_active IP Right Cessation
-
2008
- 2008-03-24 US US12/054,193 patent/US20080182873A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1472228B1 (de) | 2009-03-25 |
| CO5601005A2 (es) | 2006-01-31 |
| US7371865B2 (en) | 2008-05-13 |
| RU2299196C2 (ru) | 2007-05-20 |
| CN1622937A (zh) | 2005-06-01 |
| KR20040081161A (ko) | 2004-09-20 |
| ECSP045214A (es) | 2004-09-28 |
| US20080182873A1 (en) | 2008-07-31 |
| CA2472776C (en) | 2011-01-25 |
| CA2472776A1 (en) | 2003-08-07 |
| EP1472228A1 (de) | 2004-11-03 |
| WO2003064392A1 (en) | 2003-08-07 |
| MXPA04007396A (es) | 2004-10-11 |
| HK1070651A1 (en) | 2005-06-24 |
| BR0307303A (pt) | 2005-01-11 |
| DE60326819D1 (de) | 2009-05-07 |
| PL370658A1 (en) | 2005-05-30 |
| IL162980A (en) | 2010-02-17 |
| NO20043611L (no) | 2004-08-30 |
| JP4524111B2 (ja) | 2010-08-11 |
| CN1305853C (zh) | 2007-03-21 |
| RU2004126442A (ru) | 2005-06-10 |
| ZA200405322B (en) | 2005-07-27 |
| US20050070605A1 (en) | 2005-03-31 |
| PT1472228E (pt) | 2009-06-24 |
| NZ534232A (en) | 2006-03-31 |
| AU2003226971B2 (en) | 2006-11-30 |
| NO327091B1 (no) | 2009-04-20 |
| ES2323267T3 (es) | 2009-07-10 |
| JP2005520814A (ja) | 2005-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE426594T1 (de) | Verfahren zur herstellung von inhibitoren der hmg-coa-reduktase | |
| ATE450523T1 (de) | Verfahren zur herstellung von 3-halogen-4,5- dihydro-1 h-pyrazolen | |
| ATE453645T1 (de) | Verfahren zur herstellung von pyrrolotriazinverbindungen, die sich als kinaseinhibitoren eignen | |
| NO20062656L (no) | Fremgangsmate for fremstilling av statiner | |
| MXPA05012268A (es) | N-arilsulfonilpiperidinas enlazadas como inhibidores de la gamma-secretasa. | |
| DE60104825D1 (de) | Verfahren zur herstellung von 6-substituierten (s)-nikotin-derivaten und zwischenverbindungen | |
| EA200300804A1 (ru) | Усовершенствованный способ получения карбапенема | |
| MXPA04000357A (es) | COMPUESTO QUE CONTIENE AMIDA Y TIENE UNA MEJOR SOLUBILIDAD, Y MeTODO PARA MEJORAR LA SOLUBILIDAD DE UN COMPUESTO QUE CONTIENE AMIDA. | |
| EA200301120A1 (ru) | Цитрат 5,8,14-триазатетрацикло (10.3.1.0.0)-гексадека-2 (11),3,5,7,9-пентаена | |
| ATE521587T1 (de) | Verfahren zur herstellung von (z)-1-phenyl-1- diethylaminocarbonyl-2- aminomethylcyclopropanhydrochlorid | |
| ATE407127T1 (de) | Verfahren zur herstellung von beraprost und dessen salzen | |
| UA85428C2 (ru) | Способ получения с-2, с-3 замещенных n-алкилированных индолов, а также промежуточные соединения и способы их получения | |
| EP2266971A3 (de) | HIV-Protease inhibierende Verbindungen | |
| DE60101786D1 (de) | Verfahren zur herstellung von citalopram | |
| ATE496038T1 (de) | Verfahren zur herstellung von quetiapin | |
| ATE282594T1 (de) | Verfahren zur herstellung von (+)-trans-4-p- fluorophenyl-3-hydroxymethyl-1-methylpiperidin | |
| ATE280769T1 (de) | Verfahren zur herstellung von vitronectin- rezeptorantagonisten | |
| ATE370950T1 (de) | Verfahren zur herstellung von (1s,4r)-cis-4-(2- amino-6-chlor-9h-purin-9-yl)-2-cyclopenten-1- methanol | |
| DE602004030091D1 (de) | Verfahren zur reduktiven deshalogenierung | |
| ATE330612T1 (de) | Verfahren zur herstellung von benazeprilhydrochloride | |
| ATE387423T1 (de) | Verfahren zur herstellung der enantiomeren formen von 2,3-diaminopropionsäurederivaten | |
| ATE469119T1 (de) | Verfahren zur herstellung von polymorphen von sertralin hydrochlorid | |
| DE50312447D1 (de) | Verfahren zur herstellung von 4,6-dichlor-5-fluorpyrimidin | |
| ATE383336T1 (de) | Arylpyrrol mit antitubulinwirkung, arylfulran- und arylthiopenderivate, verfahren zur herstellung und verwendung als antimitotikum | |
| ATE421953T1 (de) | Verfahren zur racemisierung von 1-benzyl-4-(4- fluorophenyl)-3-hydroxymethyl-1,2,3,6- tetrahydropyridin und dessen verwendung in der synthese von paroxetin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1472228 Country of ref document: EP |